Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

Trial Profile

Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Acronyms VISMONEO
  • Most Recent Events

    • 11 Oct 2016 Results reporting characteristics of patients with locally advanced basal cell carcinoma and treated with neoadjuvant vismodegib and surgical resection, presented at the 41st European Society for Medical Oncology Congress.
    • 26 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 05 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by European Clinical Trials Database (EudraCT) record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top